Tenascin-C drives cardiovascular dysfunction in a mouse model of diabetic cardiomyopathy

https://m2.mtmt.hu/ hun 2026-10-23 03:15 JournalArticle 36171921 VALIDATED true Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Wahringer Gürtel 18-20, Vienna, 1090, Austria Cellular and Translational Physiology Department, Institute of Physiology, Ruhr University Bochum, Bochum, Germany Molecular and Experimental Cardiology, Ruhr University Bochum, Bochum, Germany Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany Department of Physiology, Cardiovascular Research Institute, University Maastricht, Maastricht, Netherlands HCEMM-SU Cardiovascular Comorbidities Research Group, Department of Pharmacology and Pharmacotherapy, Center for Pharmacology and Drug Research and Development, Semmelweis University, Budapest, 1089, Hungary Cardiometabolic and HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary Center for Pharmacology and Drug Research and Development, Semmelweis University, Budapest, Hungary Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary Department of Morphology and Physiology, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary Division of Cardiology, Department of Medicine, Karolinska Institutet, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden Center for Translational and Experimental Cardiology (CTEC), Zurich University Hospital, University of Zurich, Zurich, Switzerland University Heart Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria Division of Medicinal Chemistry, Otto Loewi Research Center, Medical University of Graz, Graz, Austria Department of Laboratory Medicine and Core Facilities (M.B.), Medical University of Vienna, Vienna, Austria Pharmahungary Group, Szeged, Hungary Export Date: 10 July 2025; Cited By: 0; Correspondence Address: A. Kiss; Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Wahringer Gürtel 18-20, 1090, Austria; email: attila.kiss@meduniwien.ac.at; CODEN: CDAIA 0 false 2026-09-28T11:04:23.461+0000 2025-10-08T13:44:09.167+0000 2025-06-01T14:02:34.726+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 2026-03-27T10:21:27.397+0000 2026-03-27T10:21:27.397+0000 2025-06-12T07:33:54.788+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true Admin 10025544 /api/admin/10025544 Lévayné Deseő Katalin (MTMT Központi admin) Lévayné Deseő Katalin true 10025544 true 2026-06-09T18:53:22.980+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Arnold, Zsuzsanna Tenascin-C drives cardiovascular dysfunction in a mouse model of diabetic cardiomyopathy true true /api/journal/10011378 REVIEWED CARDIOVASCULAR DIABETOLOGY 1475-2840 1475-2840 true false 10011378 false 10011378 true 1475-2840 1475-2840 Journal FOREIGN 24 1 235 235 24 2025 Funding 2053559 /api/funding/2053559 HCEMM(739593) Támogató: Horizon 2020 false true Funding 2053560 /api/funding/2053560 (EFOP-3.6.3-VEKOP-16-2017-00009) false true true true 2025 true true true false true false GOLD 2026-09-28 false http://www.cardiab.com/ 10 0 10 8 0 10 10 10 10 10 10 8 8 8 2 0 10 8 10 8 0 6 6 Folyóiratcikk Journal Article 24 10 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 3 2 3 2 2026 0 7 6 7 6 D1 false false false false 2025-05-31T14:08:55.097+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); HUN-REN-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI); Morfológiai és Fiziológiai Tanszék (SE / ETK2007); Élettani Intézet (SE / AOK / I) 6 34 5 24 0 true 10025544 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 126776765 /api/authorship/126776765 Arnold, Zsuzsanna 1 0.041666668 true false false Arnold Zsuzsanna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776766 /api/authorship/126776766 Dostal, Christopher 2 0.041666668 false false false Dostal Christopher true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776767 /api/authorship/126776767 Szabó, Petra Lujza 3 0.041666668 false false false Szabó Petra Lujza true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776768 /api/authorship/126776768 Aykac, Ibrahim 4 0.041666668 false false false Aykac Ibrahim true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776769 /api/authorship/126776769 Goncalves, Ana Isabel Antunes 5 0.041666668 false false false Goncalves Ana Isabel Antunes true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776770 /api/authorship/126776770 Sousa, Silva Laura 6 0.041666668 false false false Sousa Silva Laura true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776771 /api/authorship/126776771 Baydar, Simge 7 0.041666668 false false false Baydar Simge true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776772 /api/authorship/126776772 Budde, Heidi 8 0.041666668 false false false Budde Heidi true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776773 /api/authorship/126776773 Váradi, Barnabás [Váradi, Barnabás (Farmakológia), szerző] HUN-REN-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 9 0.042 false false false Author 10076998 /api/author/10076998 Váradi Barnabás (Farmakológia) Váradi Barnabás true true Váradi Barnabás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776774 /api/authorship/126776774 Nadasy, György L. [Nádasy, György László (Keringésélettan), szerző] Élettani Intézet (SE / AOK / I) 10 0.042 false false false Author 10023262 /api/author/10023262 Nádasy György László (Keringésélettan) Nádasy György László true 10023262 true Nadasy György L. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776775 /api/authorship/126776775 Szekeres, Mária [Szekeres, Mária (Élettan), szerző] Morfológiai és Fiziológiai Tanszék (SE / ETK2007) 11 0.042 false false false Author 10019335 /api/author/10019335 Szekeres Mária (Élettan) Szekeres Mária true 10019335 true Szekeres Mária true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776776 /api/authorship/126776776 Hage, Camilla 12 0.041666668 false false false Hage Camilla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776777 /api/authorship/126776777 Lund, Lars H. 13 0.041666668 false false false Lund Lars H. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776778 /api/authorship/126776778 Costantino, Sarah 14 0.041666668 false false false Costantino Sarah true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776779 /api/authorship/126776779 Abraham, Dietmar 15 0.041666668 false false false Abraham Dietmar true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776780 /api/authorship/126776780 Zins, Karin 16 0.041666668 false false false Zins Karin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776781 /api/authorship/126776781 Hallström, Seth 17 0.041666668 false false false Hallström Seth true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776782 /api/authorship/126776782 Bilban, Martin 18 0.041666668 false false false Bilban Martin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776783 /api/authorship/126776783 Ágg, Bence [Ágg, Bence (Farmakológia), szerző] HUN-REN-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 19 0.042 false false false Author 10057401 /api/author/10057401 Ágg Bence (Farmakológia) Ágg Bence true 10057401 true Ágg Bence true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776784 /api/authorship/126776784 Hamdani, Nazha [Hamdani, Nazha (Medicine), szerző] HUN-REN-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 20 0.042 false false false Author 10086357 /api/author/10086357 Hamdani Nazha (Medicine) Hamdani Nazha true true Hamdani Nazha true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776785 /api/authorship/126776785 Ferdinandy, Péter [Ferdinandy, Péter (Farmakológia, mol...), szerző] HUN-REN-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 21 0.042 false false false Author 10010125 /api/author/10010125 Ferdinandy Péter (Farmakológia, molekuláris medicina) Ferdinandy Péter true 10010125 true Ferdinandy Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776786 /api/authorship/126776786 Paneni, Francesco 22 0.041666668 false false false Paneni Francesco true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776787 /api/authorship/126776787 Kiss, Attila ✉ 23 0.042 false false true Kiss Attila true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126776788 /api/authorship/126776788 Podesser, Bruno K. 24 0.041666668 false true false Podesser Bruno K. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 29442709 /api/publicationidentifier/29442709 DOI: 10.1186/s12933-025-02780-y PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1186/s12933-025-02780-y https://doi.org/10.1186/s12933-025-02780-y false true PublicationIdentifier 29476303 /api/publicationidentifier/29476303 WoS: 001499643300003 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001499643300003 https://www.webofscience.com/wos/woscc/full-record/001499643300003 true true PublicationIdentifier 29463001 /api/publicationidentifier/29463001 Scopus: 105006917579 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105006917579 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105006917579 false true PublicationIdentifier 29442710 /api/publicationidentifier/29442710 PubMed: 40450269 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 40450269 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40450269&dopt=Abstract false true Classification 12197 /api/classification/12197 Gyógyszerészet, farmakogenomika, gyógyszerkutatás és tervezés, gyógyszeres kezelés true true SjrRating 11563296 /api/sjrrating/11563296 sjr:D1 (2025) Scopus - Cardiology and Cardiovascular Medicine CARDIOVASCULAR DIABETOLOGY 1475-2840 1475-2840 10 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2705 /api/classificationexternal/2705 Scopus - Cardiology and Cardiovascular Medicine true 2705 true D1 DIRECT true true Reference 66118822 /api/reference/66118822 1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2019;157:107843., DOI: 10.1016/j.diabres.2019.107843 1 10.1016/j.diabres.2019.107843 false true Reference 66118823 /api/reference/66118823 2. WHO: Cause-specific mortality, 2000–2019. In.; 2020. 2 false true Reference 66118824 /api/reference/66118824 3. Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, Standl E, Beulens JW. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2):25–32., DOI: 10.1177/2047487319878371 3 10.1177/2047487319878371 false true Reference 66118825 /api/reference/66118825 4. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241(19):2035–8., DOI: 10.1001/jama.1979.03290450033020 4 10.1001/jama.1979.03290450033020 false true Reference 66118826 /api/reference/66118826 5. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595–602., DOI: 10.1016/0002-9149(72)90595-4 5 10.1016/0002-9149(72)90595-4 false true Reference 66118827 /api/reference/66118827 6. Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000;101(19):2271–6., DOI: 10.1161/01.CIR.101.19.2271 6 10.1161/01.CIR.101.19.2271 false true Reference 66118828 /api/reference/66118828 7. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27(3):699–703., DOI: 10.2337/diacare.27.3.699 7 10.2337/diacare.27.3.699 false true Reference 66118829 /api/reference/66118829 8. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614–9., DOI: 10.2337/diacare.24.9.1614 8 10.2337/diacare.24.9.1614 false true Reference 66118830 /api/reference/66118830 9. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543–67., DOI: 10.1210/er.2003-0012 9 10.1210/er.2003-0012 false true Reference 66118831 /api/reference/66118831 10. Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17(9):585–607., DOI: 10.1038/s41569-020-0339-2 10 10.1038/s41569-020-0339-2 false true Reference 66118832 /api/reference/66118832 11. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–38., DOI: 10.1161/CIRCRESAHA.117.311586 11 10.1161/CIRCRESAHA.117.311586 false true Reference 66118833 /api/reference/66118833 12. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213–23., DOI: 10.1161/CIRCULATIONAHA.106.679597 12 10.1161/CIRCULATIONAHA.106.679597 false true Reference 66118834 /api/reference/66118834 13. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2013;18:149–66., DOI: 10.1007/s10741-012-9313-3 13 10.1007/s10741-012-9313-3 false true Reference 66118835 /api/reference/66118835 14. Frangogiannis NG. The extracellular matrix in ischemic and nonischemic heart failure. Circ Res. 2019;125(1):117–46., DOI: 10.1161/CIRCRESAHA.119.311148 14 10.1161/CIRCRESAHA.119.311148 false true Reference 66118836 /api/reference/66118836 15. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. 2006;47(4):693–700., DOI: 10.1016/j.jacc.2005.09.050 15 10.1016/j.jacc.2005.09.050 false true Reference 66118837 /api/reference/66118837 16. Tuleta I, Frangogiannis NG. Diabetic fibrosis. BBA Mol Basis Dis. 2021;1867(4):166044., DOI: 10.1016/j.bbadis.2020.166044 16 10.1016/j.bbadis.2020.166044 false true Reference 66118838 /api/reference/66118838 17. Vasanthi M, Adole PS, Pandit VR, Vinod KV. Assessment of serum tenascin-C and growth differentiation factor-15 among type 2 diabetes mellitus patients with and without acute coronary syndrome. J Med Biochem. 2020;39(4):460., DOI: 10.5937/jomb0-24662 17 10.5937/jomb0-24662 false true Reference 66118839 /api/reference/66118839 18. Gellen B, Thorin-Trescases N, Thorin E, Gand E, Sosner P, Brishoual S, Rigalleau V, Montaigne D, Javaugue V, Pucheu Y. Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort. Diabetologia. 2020;63:915–23., DOI: 10.1007/s00125-020-05108-5 18 10.1007/s00125-020-05108-5 false true Reference 66118840 /api/reference/66118840 19. Gonçalves IF, Acar E, Costantino S, Szabo PL, Hamza O, Tretter EV, Klein KU, Trojanek S, Abraham D, Paneni F. Epigenetic modulation of tenascin C in the heart: Implications on myocardial ischemia, hypertrophy and metabolism. J Hypertens. 2019;37(9):1861–70., DOI: 10.1097/HJH.0000000000002097 19 10.1097/HJH.0000000000002097 false true Reference 66118841 /api/reference/66118841 20. Santer D, Nagel F, Gonçalves IF, Kaun C, Wojta J, Fagyas M, Krššák M, Balogh Á, Papp Z, Tóth A. Tenascin-C aggravates ventricular dilatation and angiotensin-converting enzyme activity after myocardial infarction in mice. ESC Heart Failure. 2020;7(5):2113–22., DOI: 10.1002/ehf2.12794 20 10.1002/ehf2.12794 false true Reference 66118842 /api/reference/66118842 21. Yokokawa T, Sugano Y, Nakayama T, Nagai T, Matsuyama TA, Ohta-Ogo K, Ikeda Y, Ishibashi-Ueda H, Nakatani T, Yasuda S. Significance of myocardial tenascin-C expression in left ventricular remodelling and long-term outcome in patients with dilated cardiomyopathy. Eur J Heart Fail. 2016;18(4):375–85., DOI: 10.1002/ejhf.464 21 10.1002/ejhf.464 false true Reference 66118843 /api/reference/66118843 22. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell. 1986;47(1):131–9., DOI: 10.1016/0092-8674(86)90374-0 22 10.1016/0092-8674(86)90374-0 false true Reference 66118844 /api/reference/66118844 23. Chiquet-Ehrismann R, Hagios C, Schenk S. The complexity in regulating the expression of tenascins. BioEssays. 1995;17(10):873–8., DOI: 10.1002/bies.950171009 23 10.1002/bies.950171009 false true Reference 66118845 /api/reference/66118845 24. Midwood KS, Chiquet M, Tucker RP, Orend G. Tenascin-C at a glance. J Cell Sci. 2016;129(23):4321–7., DOI: 10.1242/jcs.190546 24 10.1242/jcs.190546 false true Reference 66118846 /api/reference/66118846 25. Imanaka-Yoshida K. Tenascin-C in cardiovascular tissue remodeling-from development to inflammation and repair–. Circ J. 2012;76(11):2513–20., DOI: 10.1253/circj.CJ-12-1033 25 10.1253/circj.CJ-12-1033 false true Reference 66118847 /api/reference/66118847 26. Imanaka-Yoshida K, Tawara I, Yoshida T. Tenascin-C in cardiac disease: a sophisticated controller of inflammation, repair, and fibrosis. Am J Physiol Cell Physiol. 2020;319(5):C781–96., DOI: 10.1152/ajpcell.00353.2020 26 10.1152/ajpcell.00353.2020 false true Reference 66118848 /api/reference/66118848 27. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009;3:287–310., DOI: 10.1007/s12079-009-0075-1 27 10.1007/s12079-009-0075-1 false true Reference 66118849 /api/reference/66118849 28. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest. 2001;81(7):1015–24., DOI: 10.1038/labinvest.3780313 28 10.1038/labinvest.3780313 false true Reference 66118850 /api/reference/66118850 29. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol. 2005;167(1):71–80., DOI: 10.1016/S0002-9440(10)62954-9 29 10.1016/S0002-9440(10)62954-9 false true Reference 66118851 /api/reference/66118851 30. Podesser BK, Kreibich M, Dzilic E, Santer D, Förster L, Trojanek S, Abraham D, Krššák M, Klein KU, Tretter EV. Tenascin-C promotes chronic pressure overload-induced cardiac dysfunction, hypertrophy and myocardial fibrosis. J Hypertens. 2018;36(4):847–56., DOI: 10.1097/HJH.0000000000001628 30 10.1097/HJH.0000000000001628 false true Reference 66118852 /api/reference/66118852 31. Kiss A, Nadasy GL, Fees A, Arnold Z, Aykac I, Dostal C, Szabó GT, Szabó PL, Szekeres M, Pokreisz P. Alterations in coronary resistance artery network geometry in diabetes and the role of tenascin C. Rev Cardiovasc Med. 2023. https://doi.org/10.31083/j.rcm2401006., DOI: 10.31083/j.rcm2401006 31 10.31083/j.rcm2401006 false true Reference 66118853 /api/reference/66118853 32. Nakao N, Hiraiwa N, Yoshiki A, Ike F, Kusakabe M. Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. Am J Pathol. 1998;152(5):1237. 32 false true Reference 66118854 /api/reference/66118854 33. Matsuda A, Yoshiki A, Tagawa Y, Matsuda H, Kusakabe M. Corneal wound healing in tenascin knockout mouse. Invest Ophthalmol Vis Sci. 1999;40(6):1071–80. 33 false true Reference 66118855 /api/reference/66118855 34. Mackie EJ, Tucker RP. The tenascin-C knockout revisited. J Cell Sci. 1999;112(22):3847–53., DOI: 10.1242/jcs.112.22.3847 34 10.1242/jcs.112.22.3847 false true Reference 66118856 /api/reference/66118856 35. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev. 1992;6(10):1821–31., DOI: 10.1101/gad.6.10.1821 35 10.1101/gad.6.10.1821 false true Reference 66118857 /api/reference/66118857 36. Furman BL. Streptozotocin-induced diabetic models in mice and rats. Current protocols. 2021;1(4):e78., DOI: 10.1002/cpz1.78 36 10.1002/cpz1.78 false true Reference 66118858 /api/reference/66118858 37. Bueno-Beti C, Lim CX, Protonotarios A, Szabo PL, Westaby J, Mazic M, Sheppard MN, Behr E, Hamza O, Kiss A. An mTORC1-dependent mouse model for cardiac sarcoidosis. J Am Heart Assoc. 2023;12(19):e030478., DOI: 10.1161/JAHA.123.030478 37 10.1161/JAHA.123.030478 false true Reference 66118859 /api/reference/66118859 38. Borbély A, Van Der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111(6):774–81., DOI: 10.1161/01.CIR.0000155257.33485.6D 38 10.1161/01.CIR.0000155257.33485.6D false true Reference 66118860 /api/reference/66118860 39. Hamdani N, Krysiak J, Kreusser MM, Neef S, Dos Remedios CG, Maier LS, Krüger M, Backs J, Linke WA. Crucial role for Ca2+/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res. 2013;112(4):664–74., DOI: 10.1161/CIRCRESAHA.111.300105 39 10.1161/CIRCRESAHA.111.300105 false true Reference 66118861 /api/reference/66118861 40. Kiss A, Wu P, Schlederer M, Pilz PM, Szabo PL, Li J, Weber L, Vraka C, Pichler V, Mitterhauser M. Sympathetic nerve innervation and metabolism in ischemic myocardium in response to remote ischemic perconditioning. Basic Res Cardiol. 2022;117(1):42., DOI: 10.1007/s00395-022-00946-3 40 10.1007/s00395-022-00946-3 false true Reference 66118862 /api/reference/66118862 41. Szekeres M, Nádasy GL, Turu G, Soltész-Katona E, Benyó Z, Offermanns S, Ruisanchez É, Szabó E, Takáts Z, Bátkai S. Endocannabinoid-mediated modulation of Gq/11 protein-coupled receptor signaling-induced vasoconstriction and hypertension. Mol Cell Endocrinol. 2015;403:46–56., DOI: 10.1016/j.mce.2015.01.012 41 10.1016/j.mce.2015.01.012 false true Reference 66118863 /api/reference/66118863 42. Bányai B, Vass Z, Kiss S, Balogh A, Brandhuber D, Karvaly G, Kovács K, Nádasy GL, Hunyady L, Dörnyei G. Role of CB1 cannabinoid receptors in vascular responses and vascular remodeling of the aorta in female mice. Int J Mol Sci. 2023;24(22):16429., DOI: 10.3390/ijms242216429 42 10.3390/ijms242216429 false true Reference 66118864 /api/reference/66118864 43. Perera-Gonzalez M, Kiss A, Kaiser P, Holzweber M, Nagel F, Watzinger S, Acar E, Szabo PL, Gonçalves IF, Weber L. The role of tenascin C in cardiac reverse remodeling following banding-debanding of the ascending aorta. Int J Mol Sci. 2021;22(4):2023., DOI: 10.3390/ijms22042023 43 10.3390/ijms22042023 false true Reference 66118865 /api/reference/66118865 44. Ackers-Johnson M, Li PY, Holmes AP, O’Brien S-M, Pavlovic D, Foo RS. A simplified, Langendorff-free method for concomitant isolation of viable cardiac myocytes and nonmyocytes from the adult mouse heart. Circ Res. 2016;119(8):909–20., DOI: 10.1161/CIRCRESAHA.116.309202 44 10.1161/CIRCRESAHA.116.309202 false true Reference 66118866 /api/reference/66118866 45. Costantino S, Paneni F, Battista R, Castello L, Capretti G, Chiandotto S, Tanese L, Russo G, Pitocco D, Lanza GA. Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA1c levels. Diabetes. 2017;66(9):2472–82., DOI: 10.2337/db17-0294 45 10.2337/db17-0294 false true Reference 66118867 /api/reference/66118867 46. Faxén UL, Hage C, Benson L, Zabarovskaja S, Andreasson A, Donal E, Daubert J-C, Linde C, Brismar K, Lund LH. HFpEF and HFrEF display different phenotypes as assessed by IGF-1 and IGFBP-1. J Cardiac Fail. 2017;23(4):293–303., DOI: 10.1016/j.cardfail.2016.06.008 46 10.1016/j.cardfail.2016.06.008 false true Reference 66118868 /api/reference/66118868 47. Golledge J, Clancy P, Maguire J, Lincz L, Koblar S. The role of tenascin C in cardiovascular disease. Cardiovasc Res. 2011;92(1):19–28., DOI: 10.1093/cvr/cvr183 47 10.1093/cvr/cvr183 false true Reference 66118869 /api/reference/66118869 48. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol. 2006;47(11):2319–25., DOI: 10.1016/j.jacc.2006.03.033 48 10.1016/j.jacc.2006.03.033 false true Reference 66118870 /api/reference/66118870 49. Santer D, Nagel F, Kreibich M, Dzilic E, Moser PT, Muschitz G, Inci M, Krssak M, Plasenzotti R, Bergmeister H. In vivo and ex vivo functional characterization of left ventricular remodelling after myocardial infarction in mice. ESC heart failure. 2015;2(3):171–7., DOI: 10.1002/ehf2.12039 49 10.1002/ehf2.12039 false true Reference 66118871 /api/reference/66118871 50. Franz M, Berndt A, Altendorf-Hofmann A, Fiedler N, Richter P, Schumm J, Fritzenwanger M, Figulla HR, Brehm BR. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail. 2009;11(11):1057–62., DOI: 10.1093/eurjhf/hfp128 50 10.1093/eurjhf/hfp128 false true Reference 66118872 /api/reference/66118872 51. Li M, Wu M, Zhu H, Hua Y, Ma Z, Yao J, Feng B, Shi B. Serum tenascin-C and alarin levels are associated with cardiovascular diseases in type 2 diabetes mellitus. Int J Endocrinol. 2022;2022(1):2009724. 51 false true Reference 66118873 /api/reference/66118873 52. Yonebayashi S, Tajiri K, Li S, Sato A. Tenascin-C: an emerging prognostic biomarker in diabetes. Ann Transl Med. 2020;8(24):1699., DOI: 10.21037/atm-2020-116 52 10.21037/atm-2020-116 false true Reference 66118874 /api/reference/66118874 53. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J. 2007;71(3):327–30., DOI: 10.1253/circj.71.327 53 10.1253/circj.71.327 false true Reference 66118875 /api/reference/66118875 54. Sato A, Hiroe M, Akiyama D, Hikita H, Nozato T, Hoshi T, Kimura T, Wang Z, Sakai S, Imanaka-Yoshida K. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. J Cardiac Fail. 2012;18(6):480–6., DOI: 10.1016/j.cardfail.2012.02.009 54 10.1016/j.cardfail.2012.02.009 false true Reference 66118876 /api/reference/66118876 55. Tsukada B, Terasaki F, Shimomura H, Otsuka K, Otsuka K, Katashima T, Fujita S, Imanaka-Yoshida K, Yoshida T, Hiroe M. High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation. Hum Pathol. 2009;40(7):1015–22., DOI: 10.1016/j.humpath.2008.12.017 55 10.1016/j.humpath.2008.12.017 false true Reference 66118877 /api/reference/66118877 56. Kobayashi Y, Yoshida S, Zhou Y, Nakama T, Ishikawa K, Arima M, Nakao S, Sassa Y, Takeda A, Hisatomi T. Tenascin-C promotes angiogenesis in fibrovascular membranes in eyes with proliferative diabetic retinopathy. Mol Vis. 2016;22:436. 56 false true Reference 66118878 /api/reference/66118878 57. Castellon R, Caballero S, Hamdi HK, Atilano SR, Aoki AM, Tarnuzzer RW, Kenney MC, Grant MB, Ljubimov AV. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol Vis Sci. 2002;43(8):2758–66. 57 false true Reference 66118879 /api/reference/66118879 58. Yonebayashi S, Tajiri K, Hara M, Saito H, Suzuki N, Sakai S, Kimura T, Sato A, Sekimoto A, Fujita S. Generation of transgenic mice that conditionally overexpress tenascin-C. Front Immunol. 2021;12:620541., DOI: 10.3389/fimmu.2021.620541 58 10.3389/fimmu.2021.620541 false true Reference 66118880 /api/reference/66118880 59. De Geest B, Mishra M. Role of oxidative stress in diabetic cardiomyopathy. Antioxidants. 2022;11(4):784., DOI: 10.3390/antiox11040784 59 10.3390/antiox11040784 false true Reference 66118881 /api/reference/66118881 60. Hamo CE, DeJong C, Hartshorne-Evans N, Lund LH, Shah SJ, Solomon S, Lam CS. Heart failure with preserved ejection fraction. Nat Rev Dis Primers. 2024;10(1):55., DOI: 10.1038/s41572-024-00540-y 60 10.1038/s41572-024-00540-y false true Reference 66118882 /api/reference/66118882 61. Hage C, Svedlund S, Saraste A, Faxén UL, Benson L, Fermer ML, Gan L-M, Shah SJ, Lam CS, Lund LH. Association of coronary microvascular dysfunction with heart failure hospitalizations and mortality in heart failure with preserved ejection fraction: a follow-up in the PROMIS-HFpEF study. J Cardiac Fail. 2020;26(11):1016–21., DOI: 10.1016/j.cardfail.2020.08.010 61 10.1016/j.cardfail.2020.08.010 false true Reference 66118883 /api/reference/66118883 62. Shah SJ, Lam CS, Svedlund S, Saraste A, Hage C, Tan R-S, Beussink-Nelson L, Ljung Faxén U, Fermer ML, Broberg MA. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39(37):3439–50., DOI: 10.1093/eurheartj/ehy531 62 10.1093/eurheartj/ehy531 false true Reference 66118884 /api/reference/66118884 63. Patel VB, Parajuli N, Oudit GY. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. Clin Sci. 2014;126(7):471–82., DOI: 10.1042/CS20130344 63 10.1042/CS20130344 false true Reference 66118885 /api/reference/66118885 64. Salvador DB Jr, Gamba MR, Gonzalez-Jaramillo N, Gonzalez-Jaramillo V, Raguindin PFN, Minder B, Gräni C, Wilhelm M, Stettler C, Doria A. Diabetes and myocardial fibrosis: a systematic review and meta-analysis. Cardiovasc Imaging. 2022;15(5):796–808. 64 false true Reference 66118886 /api/reference/66118886 65. Fu H, Tian Y, Zhou L, Zhou D, Tan RJ, Stolz DB, Liu Y. Tenascin-C is a major component of the fibrogenic niche in kidney fibrosis. J Am Soc Nephrol. 2017;28(3):785–801., DOI: 10.1681/ASN.2016020165 65 10.1681/ASN.2016020165 false true Reference 66118887 /api/reference/66118887 66. Segers VF, Brutsaert DL, De Keulenaer GW. Cardiac remodeling: endothelial cells have more to say than just NO. Front Physiol. 2018;9:382., DOI: 10.3389/fphys.2018.00382 66 10.3389/fphys.2018.00382 false true Reference 66118888 /api/reference/66118888 67. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res. 1996;79(6):1131–42., DOI: 10.1161/01.RES.79.6.1131 67 10.1161/01.RES.79.6.1131 false true Reference 66118889 /api/reference/66118889 68. Aguilar H, Fricovsky E, Ihm S, Schimke M, Maya-Ramos L, Aroonsakool N, Ceballos G, Dillmann W, Villarreal F, Ramirez-Sanchez I. Role for high-glucose-induced protein O-GlcNAcylation in stimulating cardiac fibroblast collagen synthesis. Am J Physiol Cell Physiol. 2014;306(9):C794–804., DOI: 10.1152/ajpcell.00251.2013 68 10.1152/ajpcell.00251.2013 false true Reference 66118890 /api/reference/66118890 69. Zhang C, Shi Y, Liu C, Sudesh SM, Hu Z, Li P, Liu Q, Ma Y, Shi A, Cai H. Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease. Cardiovasc Diabetol. 2024;23(1):169., DOI: 10.1186/s12933-024-02273-4 69 10.1186/s12933-024-02273-4 false true Reference 66118891 /api/reference/66118891 70. Zuliani-Alvarez L, Marzeda AM, Deligne C, Schwenzer A, McCann FE, Marsden BD, Piccinini AM, Midwood KS. Mapping tenascin-C interaction with toll-like receptor 4 reveals a new subset of endogenous inflammatory triggers. Nat Commun. 2017;8(1):1595., DOI: 10.1038/s41467-017-01718-7 70 10.1038/s41467-017-01718-7 false true Reference 66118892 /api/reference/66118892 71. Sághy É, Vörös I, Ágg B, Kiss B, Koncsos G, Varga ZV, Görbe A, Giricz Z, Schulz R, Ferdinandy P. Cardiac miRNA expression and their mRNA targets in a rat model of prediabetes. Int J Mol Sci. 2020;21(6):2128., DOI: 10.3390/ijms21062128 71 10.3390/ijms21062128 false true Reference 66118893 /api/reference/66118893 72. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Investig. 2005;115(3):500–8., DOI: 10.1172/JCI200524408 72 10.1172/JCI200524408 false true Reference 66118894 /api/reference/66118894 73. Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models to disease mechanisms. J Endocrinol. 2014;220(2):T1., DOI: 10.1530/JOE-13-0584 73 10.1530/JOE-13-0584 false true Reference 66118895 /api/reference/66118895 74. Krüger M, Babicz K, von Frieling-Salewsky M, Linke WA. Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy. J Mol Cell Cardiol. 2010;48(5):910–6., DOI: 10.1016/j.yjmcc.2010.02.012 74 10.1016/j.yjmcc.2010.02.012 false true Reference 66118896 /api/reference/66118896 75. Oettgen P. Regulation of vascular inflammation and remodeling by ETS factors. Circ Res. 2006;99(11):1159–66., DOI: 10.1161/01.RES.0000251056.85990.db 75 10.1161/01.RES.0000251056.85990.db false true Reference 66118897 /api/reference/66118897 76. Nan J, Wang Y, Yang J, Stark GR. IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression. Proc Natl Acad Sci. 2018;115(15):3906–11., DOI: 10.1073/pnas.1714102115 76 10.1073/pnas.1714102115 false true Reference 66118898 /api/reference/66118898 77. Frank CH, Muhammad AQ, Zahra H, Lina TAK, Dmytro I, Khatija P, Salem RKDY, Annie J, Murat O, Haider R. Ventricular myocyte contraction, intracellular calcium and expression of genes encoding cardiac muscle proteins in young and ageing Zucker diabetic fatty rat heart. Hamdan Med J. 2012;5(2):165–72., DOI: 10.7707/hmj.v5i2.140 77 10.7707/hmj.v5i2.140 false true Reference 66118899 /api/reference/66118899 78. Tang YJ, Zhang Z, Yan T, Chen K, Xu GF, Xiong SQ, Wu DQ, Chen J, Jose PA, Zeng CY. Irisin attenuates type 1 diabetic cardiomyopathy by anti-ferroptosis via SIRT1-mediated deacetylation of p53. Cardiovasc Diabetol. 2024;23(1):116., DOI: 10.1186/s12933-024-02183-5 78 10.1186/s12933-024-02183-5 false true Reference 66118900 /api/reference/66118900 79. Tuleta I, Hanna A, Humeres C, Aguilan JT, Sidoli S, Zhu F, Frangogiannis NG. Fibroblast-specific TGF-β signaling mediates cardiac dysfunction, fibrosis, and hypertrophy in obese diabetic mice. Cardiovasc Res. 2024;120:2047–63., DOI: 10.1093/cvr/cvae210 79 10.1093/cvr/cvae210 false true Reference 66118901 /api/reference/66118901 80. Gu J, Wang S, Guo H, Tan Y, Liang Y, Feng A, Liu Q, Damodaran C, Zhang Z, Keller BB. Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis. Cell Death Dis. 2018;9(2):82., DOI: 10.1038/s41419-017-0093-5 80 10.1038/s41419-017-0093-5 false true Reference 66118902 /api/reference/66118902 81. Liu X, Burke RM, Lighthouse JK, Baker CD, Dirkx RA Jr, Kang B, Chakraborty Y, Mickelsen DM, Twardowski JJ, Mello SS. p53 Regulates the extent of fibroblast proliferation and fibrosis in left ventricle pressure overload. Circ Res. 2023;133(3):271–87., DOI: 10.1161/CIRCRESAHA.121.320324 81 10.1161/CIRCRESAHA.121.320324 false true Reference 66118903 /api/reference/66118903 82. Chen B, Li R, Hernandez SC, Hanna A, Su K, Shinde AV, Frangogiannis NG. Differential effects of Smad2 and Smad3 in regulation of macrophage phenotype and function in the infarcted myocardium. J Mol Cell Cardiol. 2022;171:1–15., DOI: 10.1016/j.yjmcc.2022.06.009 82 10.1016/j.yjmcc.2022.06.009 false true Reference 66118904 /api/reference/66118904 83. Dorn LE, Petrosino JM, Wright P, Accornero F. CTGF/CCN2 is an autocrine regulator of cardiac fibrosis. J Mol Cell Cardiol. 2018;121:205–11., DOI: 10.1016/j.yjmcc.2018.07.130 83 10.1016/j.yjmcc.2018.07.130 false true Reference 66118905 /api/reference/66118905 84. Tsoutsman T, Wang X, Garchow K, Riser B, Twigg S, Semsarian C. CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure. J Mol Cell Cardiol. 2013;62:164–78., DOI: 10.1016/j.yjmcc.2013.05.019 84 10.1016/j.yjmcc.2013.05.019 false true Reference 66118906 /api/reference/66118906 85. Matsui K, Torii S, Hara S, Maruyama K, Arai T, Imanaka-Yoshida K. Tenascin-C in tissue repair after myocardial infarction in humans. Int J Mol Sci. 2023;24(12):10184., DOI: 10.3390/ijms241210184 85 10.3390/ijms241210184 false true Reference 66118907 /api/reference/66118907 86. Sarli B, Topsakal R, Kaya EG, Akpek M, Lam YY, Kaya MG. Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy. J Investig Med. 2013;61(4):728–32., DOI: 10.2310/JIM.0b013e3182880c11 86 10.2310/JIM.0b013e3182880c11 false true /api/publication/36171921 Arnold Zsuzsanna et al. Tenascin-C drives cardiovascular dysfunction in a mouse model of diabetic cardiomyopathy. (2025) CARDIOVASCULAR DIABETOLOGY 1475-2840 1475-2840 24 1<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> Arnold Zsuzsanna ;    Dostal Christopher ;    Szabó Petra Lujza ;    Aykac Ibrahim ;    Goncalves Ana Isabel Antunes ;    Sousa Silva Laura ;    Baydar Simge ;    Budde Heidi ;    <a href="/gui2/?type=authors&mode=browse&sel=10076998" target="_blank">Váradi Barnabás (Váradi Barnabás Farmakológia) </a> SE/AOK/I/FFI/HUN-REN-SE Rendszerfarmakológiai Kutatócsoport; SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet; SE/KSZE/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ ;    <a href="/gui2/?type=authors&mode=browse&sel=10023262" target="_blank">Nadasy György L. (Nádasy György László Keringésélettan) </a> SE/AOK/I/Élettani Intézet ;    <a href="/gui2/?type=authors&mode=browse&sel=10019335" target="_blank">Szekeres Mária (Szekeres Mária Élettan) </a> SE/ETK2007/Morfológiai és Fiziológiai Tanszék ;    Hage Camilla ;    Lund Lars H. ;    Costantino Sarah ;    Abraham Dietmar ;    Zins Karin ;    Hallström Seth ;    Bilban Martin ;    <a href="/gui2/?type=authors&mode=browse&sel=10057401" target="_blank">Ágg Bence (Ágg Bence Farmakológia) </a> SE/AOK/I/FFI/HUN-REN-SE Rendszerfarmakológiai Kutatócsoport; SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet; SE/KSZE/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ ;    <a href="/gui2/?type=authors&mode=browse&sel=10086357" target="_blank">Hamdani Nazha (Hamdani Nazha Medicine) </a> SE/AOK/I/FFI/HUN-REN-SE Rendszerfarmakológiai Kutatócsoport; SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet; SE/KSZE/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ ;    <a href="/gui2/?type=authors&mode=browse&sel=10010125" target="_blank">Ferdinandy Péter (Ferdinandy Péter Farmakológia, molekuláris medicina) </a> SE/AOK/I/FFI/HUN-REN-SE Rendszerfarmakológiai Kutatócsoport; SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet; SE/KSZE/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ ;    Paneni Francesco ;    Kiss Attila ✉ ;    Podesser Bruno K. </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36171921" target="_blank">Tenascin-C drives cardiovascular dysfunction in a mouse model of diabetic cardiomyopathy</a></div> <div> CARDIOVASCULAR DIABETOLOGY (<a target="_blank" href="https://portal.issn.org/resource/ISSN/1475-2840">1475-2840</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1475-2840">1475-2840</a>): 24 1 Paper 235. 24 p. (2025) </div> <div class="pub-footer"> Nyelv: Angol | <a style="color:blue" title="10.1186/s12933-025-02780-y" target="_blank" href="https://doi.org/10.1186/s12933-025-02780-y"> DOI </a> <a style="color:blue" title="001499643300003" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001499643300003"> WoS </a> <a style="color:blue" title="105006917579" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105006917579"> Scopus </a> <a style="color:blue" title="40450269" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40450269&dopt=Abstract"> PubMed </a> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cardiology and Cardiovascular Medicine   SJR indikátor: D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Endocrinology, Diabetes and Metabolism   SJR indikátor: D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Internal Medicine   SJR indikátor: D1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> Nyilvános idéző összesen: 10 | Független: 8 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 10 | Scopus jelölt: 10 | WoS/Scopus jelölt: 10 | DOI jelölt: 10 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36171921&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 6 </a> </div> <div class="mtid">Közlemény: 36171921 | Egyeztetett Forrás Idéző | Folyóiratcikk ( Szakcikk ) | Tudományos | kézi felvitel </div> <div class="funder"> HCEMM(739593) Támogató: Horizon 2020, (EFOP-3.6.3.-VEKOP-16-2017-00009) </div> <div class="lastModified">Utolsó módosítás: 2025.10.08. 15:44 Áncsán Gizella (SE admin) </div> <div class="lockedBy">Központi kezelésű 2026.06.09. 20:53 Lévayné Deseő Katalin (MTMT Központi admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;">Megjegyzés: Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Wahringer Gürtel 18-20, Vienna, 1090, Austria Cellular and Translational Physiology Department, Institute of Physiology, Ruhr University Bochum, Bochum, Germany Molecular and Experimental Cardiology,...</pre> </div></div>